UroGen Pharma Ltd. (URGN)

UroGen Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	95.82	56.22	45.59	54.09	50.21
Short-Term Investments	41.97	44.56	44.78	49.15	97.39
Cash & Cash Equivalents	137.79	100.78	90.37	103.24	147.6
Cash Growth	36.73%	11.52%	-12.47%	-30.05%	45.32%
Receivables	15.44	12.7	11.72	7.05	0
Inventory	5.67	4.33	4.83	1.96	0
Other Current Assets	10.28	11.1	7.48	3.36	1.03
Total Current Assets	169.19	128.91	114.39	115.62	148.63
Property, Plant & Equipment	2.36	3.75	3.15	4.2	4.71
Long-Term Investments	4.73	0.22	0.9	2.12	48.78
Other Long-Term Assets	2.04	2.74	1.31	0.07	0.26
Total Long-Term Assets	9.13	6.71	5.36	6.39	53.75
Total Assets	178.31	135.62	119.75	122.01	202.39
Accounts Payable	16.54	12.38	12.1	10.02	11.19
Other Current Liabilities	14.67	11.53	10.28	11.41	8.3
Total Current Liabilities	31.21	23.92	22.38	21.44	19.48
Long-Term Debt	99.4	99.12	0.4	1.5	2.6
Other Long-Term Liabilities	112.92	101.94	88.56	2.72	0
Total Long-Term Liabilities	212.31	201.06	88.95	4.21	2.6
Total Liabilities	243.52	224.98	111.33	25.65	22.09
Total Debt	99.4	99.12	0.4	1.5	2.6
Debt Growth	0.27%	24805.28%	-73.41%	-42.51%	-
Retained Earnings	-679.35	-577.1	-467.32	-356.5	-228.02
Comprehensive Income	0.01	-0.11	-0.03	0.27	0.28
Shareholders' Equity	-65.21	-89.36	8.41	96.36	180.3
Net Cash / Debt	38.39	1.65	89.97	101.75	145
Net Cash / Debt Growth	2221.28%	-98.16%	-11.58%	-29.83%	42.75%
Net Cash Per Share	1.33	0.07	4.03	4.67	7.06
Working Capital	137.97	104.99	92.01	94.18	129.15
Book Value Per Share	-2.26	-3.92	0.38	4.42	8.78

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).